Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in <i>KMT2A</i>-Rearranged BCP-ALL
Alina Hartmann(University Hospital Schleswig-Holstein), Claudia D. Baldus(University Hospital Schleswig-Holstein), Thomas Beder(University Hospital Schleswig-Holstein), Julia Alten(Christian-Albrechts-Universität zu Kiel), Mayukh Mondal(University Hospital Schleswig-Holstein), Martin Schrappe(University Hospital Schleswig-Holstein), Michaela Kotrová(University Hospital Schleswig-Holstein), Kerstin K. Rauwolf(University Children's Hospital Zurich), Thomas Burmeister(Sana Klinikum Lichtenberg), Fabio D. Steffen(University Children's Hospital Zurich), Nicola Goekbuget(Goethe University Frankfurt), Lorenz Bastian(University Hospital Schleswig-Holstein), Gunnar Cario, Patrick Ehm(University Hospital Schleswig-Holstein), Sonja Bendig(Munich Leukemia Laboratory (Germany)), Malwine Barz(University Children's Hospital Zurich), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Aeint-Steffen Ströh(University Hospital Schleswig-Holstein), Nadine Wolgast(University Hospital Schleswig-Holstein), Lennart Lenk(University Hospital Schleswig-Holstein), Eric Amelunxen(University Hospital Schleswig-Holstein), Monika Brüggemann(University Hospital Schleswig-Holstein), Johannes Haas(University Children's Hospital Zurich), Beat Bornhäuser(University Children's Hospital Zurich)
Cited by 0
Related Papers
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k